VIP PEPTIDE
Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide that binds to VPAC1 and VPAC2 receptors, mediating vasodilation, smooth muscle relaxation, and immunomodulation across gastrointestinal, cardiovascular, nervous, and immune systems.
Vasoactive Intestinal Peptide (VIP) is a naturally occurring neuropeptide widely distributed throughout the body, particularly abundant in the brain, gastrointestinal tract, and peripheral nervous system. It functions as a neurotransmitter and neuromodulator, influencing vasodilation, immune regulation, gastrointestinal motility, and neurological processes. VIP has been studied for its roles in migraine pathophysiology, inflammatory bowel conditions, and as a potential therapeutic agent for various gastrointestinal and neurological disorders.
Research
Reported Effects
Clinical Evidence:: Strong correlation found between VIP levels and inflammatory bowel disease activity with good sensitivity (81%) and specificity (55%) as a biomarker. Migraine Research:: Clinical trials demonstrate VIP can trigger migraine-like headaches, establishing its role in headache pathophysiology but not as a therapeutic. Limited Supplement Use:: VIP is not commonly used as a direct supplement in biohacking communities; most discussion focuses on other peptides like BPC-157 rather than VIP specifically. Research vs Practice Gap:: While VIP has established physiological roles, its therapeutic application as an exogenous supplement remains experimental with limited real-world user experience
- Strong correlation found between VIP levels and inflammatory bowel disease activity with good sensitivity (81%) and specificity (55%) as a biomarker
- Clinical trials demonstrate VIP can trigger migraine-like headaches, establishing its role in headache pathophysiology but not as a therapeutic
- VIP is not commonly used as a direct supplement in biohacking communities; most discussion focuses on other peptides like BPC-157 rather than VIP specifically
- While VIP has established physiological roles, its therapeutic application as an exogenous supplement remains experimental with limited real-world user experience
Safety Profile
Safety Profile: VIP Peptide (Vasoactive Intestinal Peptide)
Common Side Effects
- Facial flushing and generalized vasodilation are the most common effects due to potent vasodilatory activity
- Hypotension, sometimes significant, particularly with intravenous or high-dose intranasal administration
- Tachycardia (reflex response to vasodilation)
- Diarrhea and abdominal cramping due to stimulation of intestinal secretion
- Nasal irritation and rhinorrhea with intranasal administration
- Headache secondary to vasodilation
Serious Adverse Effects
- Severe hypotension and cardiovascular collapse possible with rapid IV administration or overdose
- Watery diarrhea syndrome at supratherapeutic doses (mimics VIPoma effects)
- Cardiac arrhythmias secondary to hemodynamic changes
- Bronchodilation may mask worsening of underlying pulmonary conditions
- Limited long-term human safety data; most clinical evidence from small studies in CIRS, pulmonary hypertension, and sarcoidosis
Contraindications
- Known hypersensitivity to VIP or formulation components
- Severe hypotension or hemodynamic instability
- Active diarrheal illness (VIP stimulates intestinal water and electrolyte secretion)
- VIPoma or suspected VIP-secreting tumors
- Pregnancy and lactation (insufficient safety data; potent vasodilatory effects may compromise fetal circulation)
Drug Interactions
- Antihypertensives: Severe additive hypotension risk; close blood pressure monitoring essential
- Phosphodiesterase inhibitors (sildenafil, tadalafil): Synergistic vasodilation; dangerous hypotension possible
- Beta-blockers: May prevent reflex tachycardia, worsening hypotension
- Secretin and other GI hormones: Additive effects on intestinal secretion and motility
- Corticosteroids: VIP is sometimes used alongside steroids in CIRS protocols; monitor for additive immunomodulation
Population-Specific Considerations
- CIRS patients: Primary clinical use population (intranasal); titrate slowly and monitor blood pressure
- Elderly: Higher susceptibility to hypotension; use lowest effective dose with careful monitoring
- Pediatric: Very limited safety data; use only under specialist supervision
- Pulmonary hypertension patients: Investigational use via inhalation; requires hemodynamic monitoring
- Cardiac patients: Avoid in unstable cardiovascular disease; vasodilatory effects may precipitate ischemia
Pharmacokinetic Profile
Quick Start
- Typical Dose
- Unlike common peptides discussed in biohacking communities (BPC-157, etc.), VIP lacks established dosing guidelines for supplementation purposes
Safety Profile
Common Side Effects
- Migraine Trigger:: VIP infusion can induce migraine-like headaches in susceptible individuals, particularly those with migraine history
- Limited Safety Data:: Minimal information exists about side effects from chronic exogenous VIP supplementation in humans
- Cardiovascular Effects:: As a vasoactive peptide, VIP influences blood vessel dilation and cardiovascular function, requiring monitoring in therapeutic contexts
- Unknown Long-term Effects:: The safety profile of prolonged VIP supplementation has not been adequately studied in healthy populations
References (7)
- [1]Gut-brain Axis and migraine headache: a comprehensive review
→ Reviews the bidirectional relationship between the gastrointestinal system and central nervous system in migraine, highlighting VIP's role in the gut-brain axis and its association with migraine pathophysiology and gastrointestinal disorders.
- [3]Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial
→ A clinical trial examining VIP infusion effects on migraine development, providing evidence for VIP's role as a migraine trigger and its involvement in headache pathophysiology.
- [2]Vasoactive intestinal polypeptide plasma levels associated with migraine
→ Investigates the relationship between VIP plasma levels and migraine development, suggesting VIP may cross the blood-brain barrier and play a role in anxiety, depression, and migraine mechanisms.
- [4]Vasoactive intestinal peptide as a laboratory supplement to clinical activity index in inflammatory bowel disease
→ Demonstrates that circulating VIP levels correlate strongly with clinical activity in inflammatory bowel disease, showing sensitivity and specificity as a biomarker for gauging disease severity in UC and Crohn's disease.
- [5]Immunohistochemical study of vasoactive intestinal peptide (VIP) enteric neurons in diabetic rats supplemented with L-glutamine
→ Examines how L-glutamine supplementation affects VIP-immunoreactive neurons in diabetic rats, showing changes in cell body and nerve fiber areas that suggest modulation of enteric nervous system function.
- [6]Postprandial effect of gastrointestinal hormones and gastric activity in patients with irritable bowel syndrome
→ Investigates postprandial VIP secretion and gastric activity in IBS patients, examining the role of gut peptides in altered gut regulation characteristic of irritable bowel syndrome.
- [7]The impact of exogenous vasoactive intestinal polypeptide on inflammatory responses and mRNA expression of tight junction genes in lambs fed a high-grain diet
→ Evaluates exogenous VIP administration effects on inflammation and intestinal barrier function in lambs, demonstrating VIP's impact on gut inflammatory responses and tight junction integrity.